- Featured Product
- KD/KO Validated
CXCL10/IP10 Polyclonal antibody
CXCL10/IP10 Polyclonal Antibody for IHC, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human and More (2)
Applications
IHC, ELISA and More (2)
Conjugate
Unconjugated
验证数据展示
经过测试的应用
| Positive IHC detected in | human ovary tumor tissue, human hepatocirrhosis tissue, human nasopharyngeal carcinoma tissue, human liver cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Planning an IHC experiment? We recommend our IHCeasy CXCL10/IP10 Ready-To-Use IHC Kit. CXCL10/IP10 primary antibody included.
推荐稀释比
| Application | Dilution |
|---|---|
| Immunohistochemistry (IHC) | IHC : 1:200-1:800 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
产品信息
10937-1-AP targets CXCL10/IP10 in WB, IHC, IF, ELISA applications and shows reactivity with human samples.
| Tested Applications | IHC, ELISA Application Description |
| Cited Applications | WB, IHC, IF |
| Tested Reactivity | human |
| Cited Reactivity | human, mouse, rat |
| Immunogen | CXCL10/IP10 fusion protein Ag1369 种属同源性预测 |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Full Name | chemokine (C-X-C motif) ligand 10 |
| Synonyms | C X C motif chemokine 10, C7, crg 2, CXCL10, CXCL10/IP10, Gamma IP10, gIP 10, IFI10, INP10, IP 10, IP10, mob 1, SCYB10, Small inducible cytokine B10 |
| Calculated Molecular Weight | 11 kDa |
| GenBank Accession Number | BC010954 |
| Gene Symbol | CXCL10 |
| Gene ID (NCBI) | 3627 |
| RRID | AB_2088002 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | P02778 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
背景介绍
CXCL10 (also known as IP-10) is a member of the CXC chemokine family which binds to the CXCR3 receptor to exert its biological effects. CXCL10 is a 12-kDa protein and constitutes two internal disulfide cross bridges. The predicted signal peptidase cleavage generates a 10-kDa secreted polypeptide with four conserved cysteine residues in the N-terminal. The CXCL10 gene localizes on chromosome 4 at band q21, a locus associated with an acute monocytic/B-lymphocyte lineage leukemia exhibiting translocation of t (4; 11) (q21; q23). CXCL10 mediates leukocyte trafficking, adaptive immunity, inflammation, haematopoiesis and angiogenesis. Under proinflammatory conditions CXCL10 is secreted from a variety of cells, such as leukocytes, activated neutrophils, eosinophils, monocytes, epithelial cells, endothelial cells, stromal cells (fibroblasts) and keratinocytes in response to IFN-γ.
实验方案
| Product Specific Protocols | |
|---|---|
| IHC protocol for CXCL10/IP10 antibody 10937-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
发表文章
| Species | Application | Title |
|---|---|---|
Cancer Lett PARP inhibitor plus radiotherapy reshape the immune suppressive microenvironment and potentiate the efficacy of immune checkpoint inhibitors in tumors with IDH1 mutation | ||
J Mater Chem B Magnetic hyperthermia induces effective and genuine immunogenic tumor cell death with respect to exogenous heating | ||
Front Immunol LRPPRC facilitates tumor progression and immune evasion through upregulation of m6A modification of PD-L1 mRNA in hepatocellular carcinoma | ||
Cancer Commun (Lond) KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer. | ||
Am J Cancer Res Identification of potential immune-related circRNA-miRNA-mRNA regulatory network in cutaneous squamous cell carcinoma | ||
Front Immunol CD11c+ B Cells Participate in the Pathogenesis of Graves' Disease by Secreting Thyroid Autoantibodies and Cytokines. |
